Elgethun Capital Management raised its stake in shares of Danaher Co. (NYSE:DHR – Free Report) by 3.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,517 shares of the conglomerate’s stock after buying an additional 86 shares during the period. Elgethun Capital Management’s holdings in Danaher were worth $578,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also modified their holdings of DHR. Gilbert & Cook Inc. increased its holdings in shares of Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock valued at $401,000 after purchasing an additional 42 shares during the period. Grimes & Company Inc. raised its position in Danaher by 0.6% during the 4th quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock worth $1,696,000 after buying an additional 43 shares during the last quarter. Dakota Community Bank & Trust NA lifted its stake in shares of Danaher by 16.4% in the 4th quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after acquiring an additional 45 shares during the period. Howard Capital Management Group LLC boosted its holdings in shares of Danaher by 4.1% in the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock valued at $342,000 after acquiring an additional 48 shares in the last quarter. Finally, Spinnaker Trust increased its stake in shares of Danaher by 1.2% during the fourth quarter. Spinnaker Trust now owns 4,304 shares of the conglomerate’s stock worth $988,000 after acquiring an additional 50 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Transactions at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 11.10% of the company’s stock.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on DHR
Danaher Stock Performance
NYSE DHR opened at $181.42 on Monday. The business’s 50-day simple moving average is $209.99 and its 200-day simple moving average is $233.73. The firm has a market capitalization of $129.66 billion, a P/E ratio of 34.36, a P/E/G ratio of 2.66 and a beta of 0.86. Danaher Co. has a 1-year low of $165.17 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period last year, the firm earned $2.09 EPS. Equities analysts predict that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be given a $0.32 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.71%. Danaher’s dividend payout ratio (DPR) is 24.24%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Are Penny Stocks a Good Fit for Your Portfolio?
- Buffett’s $150B Bond Move: What It Really Means for Investors
- Following Congress Stock Trades
- 3 ETFs That Offer Easy Exposure to the AI Revolution
- How to Use the MarketBeat Dividend Calculator
- 2 Ways to Win the Tarrif Trade: Toyota and Tesla
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.